Generate Biomedicines Inc(GENB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | - | Insider Own | 56.98% | Shs Outstand | 128.3M | Perf Week | 2.4% |
| Market Cap | 1.70B | Forward P/E | - | EPS next Y | -0.73% | Insider Trans | - | Shs Float | 55.2M | Perf Month | -11.4% |
| Enterprise Value | 1.30B | PEG | - | EPS next Q | -0.56 | Inst Own | 26.58% | Short Float | 16.18% | Perf Quarter | 0.99% |
| Income | - | P/S | - | EPS this Y | 49.87% | Inst Trans | 8.52% | Short Ratio | 8.16 | Perf Half Y | 5.93% |
| Sales | - | P/B | 3.72 | EPS next 5Y | 26.8% | ROA | - | Short Interest | 8.93M | Perf YTD | -11.93% |
| Book/sh | 3.56 | P/C | 3.71 | EPS past 3/5Y | - | ROE | - | 52W High | -41.73% ($22.67) | Perf Year | - |
| Cash/sh | 3.56 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 20.09% ($11.00) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 5.77% 6.44% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.88 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.3 | EPS Q/Q | - | Profit Margin | - | RSI (14) | 46.05 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.3 | Sales Q/Q | - | SMA20 | -0.38% ($13.26) | Beta | - | Target Price | $27 |
| Payout | - | Debt/Eq | 0.14 | Earnings | 2026/8/6 | SMA50 | -12.32% ($15.07) | Rel Volume | 0.69 | Prev Close | $12.35 |
| Employees | 312 | LT Debt/Eq | 0.11 | EPS/Sales Surpr. | -2.3% 19.13% | SMA200 | -5.97% ($14.05) | Avg Volume(3M) | 1.09M | Price | $13.21 |
| IPO | 2026/2/27 | Option/Short | Yes/Yes | Trades | 4779 | Volume | 757,348 | Change | 6.96% |
A US biotech company that operates a generative AI-based drug discovery platform. It leverages a generative AI platform that designs proteins and antibodies to discover and develop therapeutics targeting a wide range of diseases, maintaining a pipeline across multiple therapeutic areas. The company stands out as a differentiated biotech by combining its generative AI drug discovery platform with its pipeline.
Over the past 1 year, on the lower side
42% below its 1-year high.
Traded less than usual. That is 69% of its average volume.
Earnings are growing steadily
Earnings are expected to grow by +49.9% this year.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 26.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #116 of 594 in the industry
Based on market cap of $2B.
MESO#114 Mesoblast Ltd ADR $2B PER - 
KLRA#115 Kailera Therapeutics Inc $2B PER - GENB#116 Generate Biomedicines Inc $2B PER - 
STOK#117 Stoke Therapeutics Inc $2B PER - 
QURE#118 uniQure NV $2B PER - 
FAQ
What kind of company is GENB?
GENB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of GENB?
The market cap of GENB is approximately $1.7B, ranking 2,194 within its sector.
What is the 52-week high and low for GENB?
GENB has recorded a 52-week high of $22.67 and a low of $11.00.
